American Century Companies Inc. Buys 418,603 Shares of OraSure Technologies, Inc. (NASDAQ:OSUR)

American Century Companies Inc. lifted its position in OraSure Technologies, Inc. (NASDAQ:OSUR) by 30.1% during the 2nd quarter, HoldingsChannel reports. The firm owned 1,809,897 shares of the medical instruments supplier’s stock after acquiring an additional 418,603 shares during the quarter. American Century Companies Inc.’s holdings in OraSure Technologies were worth $7,710,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Charles Schwab Investment Management Inc. increased its stake in OraSure Technologies by 6.5% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 774,824 shares of the medical instruments supplier’s stock worth $6,354,000 after acquiring an additional 47,207 shares during the last quarter. Dimensional Fund Advisors LP increased its position in OraSure Technologies by 8.4% in the fourth quarter. Dimensional Fund Advisors LP now owns 3,906,687 shares of the medical instruments supplier’s stock worth $32,035,000 after purchasing an additional 301,558 shares during the last quarter. Dynamic Technology Lab Private Ltd purchased a new stake in OraSure Technologies during the fourth quarter valued at $113,000. Trexquant Investment LP lifted its position in OraSure Technologies by 155.6% during the fourth quarter. Trexquant Investment LP now owns 165,201 shares of the medical instruments supplier’s stock valued at $1,355,000 after purchasing an additional 100,557 shares during the last quarter. Finally, Cannell Capital LLC grew its stake in shares of OraSure Technologies by 25.8% in the 4th quarter. Cannell Capital LLC now owns 3,549,050 shares of the medical instruments supplier’s stock worth $29,102,000 after buying an additional 728,459 shares in the last quarter. 93.50% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

OSUR has been the subject of a number of analyst reports. StockNews.com downgraded shares of OraSure Technologies from a “buy” rating to a “hold” rating in a report on Saturday, August 17th. Evercore ISI raised their price objective on OraSure Technologies from $4.50 to $5.00 and gave the company an “in-line” rating in a research note on Wednesday, August 7th. Three analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. According to MarketBeat.com, OraSure Technologies presently has a consensus rating of “Hold” and a consensus price target of $6.67.

OraSure Technologies Trading Up 1.8 %

OSUR stock opened at $4.41 on Tuesday. The stock has a market cap of $326.16 million, a PE ratio of 14.70 and a beta of 0.05. OraSure Technologies, Inc. has a 12 month low of $3.91 and a 12 month high of $8.45. The company has a 50-day moving average price of $4.33 and a 200 day moving average price of $4.91.

OraSure Technologies (NASDAQ:OSUR) last announced its earnings results on Tuesday, August 6th. The medical instruments supplier reported $0.03 earnings per share (EPS) for the quarter. OraSure Technologies had a return on equity of 9.15% and a net margin of 9.88%. The business had revenue of $54.34 million during the quarter, compared to analyst estimates of $53.35 million. Sell-side analysts forecast that OraSure Technologies, Inc. will post -0.11 EPS for the current year.

OraSure Technologies Profile

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company’s products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.